Clinical Research Directory

Inclusion Criteria: * Completion of last visit (or early termination visit, if applicable) for Study Q2788g * Signed Informed Consent Form * Use of an effective method of contraception for females of childbearing potential * Body weight ≥ 20 kg and ≤ 150 kg * IgE level ≤ 1300 IU/mL (Note: Subjects with an IgE \< 30 IU/mL will be dosed at the lowest level on the dosing table \[30 IU/mL\], thus enabling better understanding of the role of Xolair in peanut allergic subjects who have low total IgE levels.) Exclusion Criteria: * Withdrawal from Study Q2788g prior to study closure or the final study visit (Week 36) * Current participation in another investigational study * Pregnancy or lactation * History of brittle asthma * Aspirin-sensitive asthma * Known hypersensitivity to any ingredients of Xolair, including its excipients (sucrose, histidine, polysorbate 20) * Have a polymorrphonuclear count \<1500/uL * Use of anti-coagulants, such as warfarin (Coumadin(R)), thrombolytic enzymes, or ticlopidine * Current diagnosis of cancer, current investigation for possible cancer, or history of cancer (not including non-melanoma skin cancer) * Thrombocytopenia as evidenced by a platelet count \< 100,000/uL * Any systemic condition requiring regular administration of an immunoglobulin